OTLK News

Latest breaking news and updates for OTLK stock.

Track all markets on TradingView

Outlook Therapeutics Requests Type A Meeting with FDA

(NASDAQ:OTLK) ISELIN, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab fo...

What impact could the outcome of the BLA resubmission have on OTLK's valuation relative to other bevacizumab‑based ophthalmic competitors? How might the FDA's feedback on ONS-5010 affect Outlook Therapeutics' cash runway and need for additional financing? What is the expected timeline for a regulatory decision following the Type A meeting and CRL response?
Regulation
8 days ago
Read more globenewswire

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

ISELIN, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment ...

How does this regulatory setback compare to recent outcomes for other biotech firms with AMD therapies, and what impact might it have on OTLK's valuation relative to its peers? What are the specific FDA concerns in the CRL, and what timeline and cost are required for additional data or studies to address them? How will the FDA's complete response letter affect Outlook Therapeutics' short‑term stock volatility and trading volume?
Regulation
14 days ago
Read more globenewswire

Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update

ISELIN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment ...

What is the market's perception of Outlook Therapeutics' competitive positioning against other bevacizumab‑based or alternative retinal disease treatments? How did the share price react to the press release historically, and what is the typical intraday volatility around such announcements? Is there any indication of partnership or licensing discussions with larger pharma companies that could provide upside?
Earnings
28 days ago
Read more globenewswire